Cargando…

Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development

BACKGROUND: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Māori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such informati...

Descripción completa

Detalles Bibliográficos
Autores principales: Williamson, Deborah A, Smeesters, Pierre R, Steer, Andrew C, Morgan, Julie, Davies, Mark, Carter, Philip, Upton, Arlo, Tong, Stephen Y.C., Fraser, John, Moreland, Nicole J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062888/
https://www.ncbi.nlm.nih.gov/pubmed/27733129
http://dx.doi.org/10.1186/s12879-016-1891-6
_version_ 1782459868336095232
author Williamson, Deborah A
Smeesters, Pierre R
Steer, Andrew C
Morgan, Julie
Davies, Mark
Carter, Philip
Upton, Arlo
Tong, Stephen Y.C.
Fraser, John
Moreland, Nicole J
author_facet Williamson, Deborah A
Smeesters, Pierre R
Steer, Andrew C
Morgan, Julie
Davies, Mark
Carter, Philip
Upton, Arlo
Tong, Stephen Y.C.
Fraser, John
Moreland, Nicole J
author_sort Williamson, Deborah A
collection PubMed
description BACKGROUND: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Māori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. METHODS: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Māori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Māori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. RESULTS: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. CONCLUSIONS: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-1891-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5062888
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50628882016-10-24 Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development Williamson, Deborah A Smeesters, Pierre R Steer, Andrew C Morgan, Julie Davies, Mark Carter, Philip Upton, Arlo Tong, Stephen Y.C. Fraser, John Moreland, Nicole J BMC Infect Dis Research Article BACKGROUND: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) are responsible for a significant disease burden amongst Māori and Pacific populations in New Zealand (NZ). However, contemporary data are lacking regarding circulating group A Streptococcal (GAS) strains in NZ. Such information is important in guiding vaccine development. METHODS: GAS isolates from April to June 2015 were recovered from skin and pharyngeal samples from children living in areas of high social deprivation in Auckland, NZ, a significant proportion of which are Māori or Pacific. These children are among the highest risk group for developing ARF. Isolates were compared to concurrently collected pharyngeal isolates from Dunedin, NZ, where both the proportion of Māori and Pacific children and risk of developing ARF is low. Emm typing, emm cluster typing and theoretical coverage of the 30-valent vaccine candidate were undertaken as previously described. RESULTS: A high diversity of emm types and a high proportion of emm-pattern D and cluster D4 isolates were detected amongst both skin and pharyngeal isolates in children at high risk of ARF. Pharyngeal isolates from children at low risk of ARF within the same country were significantly less diverse, less likely to be emm pattern D, and more likely to be theoretically covered by the 30-valent M protein vaccine. CONCLUSIONS: The high proportion of emm pattern D GAS strains amongst skin and pharyngeal isolates from children at high risk of ARF raises further questions about the role of skin infection in ARF pathogenesis. Emm types and emm clusters differed considerably between ARF endemic and non-endemic settings, even within the same country. This difference should be taken into account for vaccine development. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-016-1891-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-12 /pmc/articles/PMC5062888/ /pubmed/27733129 http://dx.doi.org/10.1186/s12879-016-1891-6 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Williamson, Deborah A
Smeesters, Pierre R
Steer, Andrew C
Morgan, Julie
Davies, Mark
Carter, Philip
Upton, Arlo
Tong, Stephen Y.C.
Fraser, John
Moreland, Nicole J
Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title_full Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title_fullStr Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title_full_unstemmed Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title_short Comparative M-protein analysis of Streptococcus pyogenes from pharyngitis and skin infections in New Zealand: Implications for vaccine development
title_sort comparative m-protein analysis of streptococcus pyogenes from pharyngitis and skin infections in new zealand: implications for vaccine development
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5062888/
https://www.ncbi.nlm.nih.gov/pubmed/27733129
http://dx.doi.org/10.1186/s12879-016-1891-6
work_keys_str_mv AT williamsondeboraha comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT smeesterspierrer comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT steerandrewc comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT morganjulie comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT daviesmark comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT carterphilip comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT uptonarlo comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT tongstephenyc comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT fraserjohn comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment
AT morelandnicolej comparativemproteinanalysisofstreptococcuspyogenesfrompharyngitisandskininfectionsinnewzealandimplicationsforvaccinedevelopment